Reference number : GC-2017-Q1-00376, amendment number : , agreement type : G, recipient legal name : Hein, Jason (The University of British Columbia), recipient country : CA, recipient province : nan, recipient city : British Columbia|Colombie-Britannique, recipient postal code : nan, program name english : Engage Grants for Universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Control of crystallite particle size distribution is essential in the manufacturing of pharmaceutical dosage_x000D_
forms. In particular, obtaining a narrow size distribution is essential to enable new sustained release technology_x000D_
developed by Eupraxia pharmaceuticals. The present workflow presents a significant barrier to scale up and_x000D_
manufacturing of a novel anti-inflammatory therapy. New techniques designed by the Hein lab, which_x000D_
leverages automation and in situ monitoring technology, will help to identify optimal crystallization conditions_x000D_
to achieve a narrow and controlled particle size distribution for the active pharmaceutical ingredient. In_x000D_
addition, the Hein lab will investigate adapting the optimized crystallization process into a continuous_x000D_
crystallization workflow, making the final manufacturing stage robust and very efficient., program purpose french : Control of crystallite particle size distribution is essential in the manufacturing of pharmaceutical dosage_x000D_
forms. In particular, obtaining a narrow size distribution is essential to enable new sustained release technology_x000D_
developed by Eupraxia pharmaceuticals. The present workflow presents a significant barrier to scale up and_x000D_
manufacturing of a novel anti-inflammatory therapy. New techniques designed by the Hein lab, which_x000D_
leverages automation and in situ monitoring technology, will help to identify optimal crystallization conditions_x000D_
to achieve a narrow and controlled particle size distribution for the active pharmaceutical ingredient. In_x000D_
addition, the Hein lab will investigate adapting the optimized crystallization process into a continuous_x000D_
crystallization workflow, making the final manufacturing stage robust and very efficient., agreement title english : Harnessing the benefits of continuous crystallization to precisely control particular size_x000D_
distribution of active pharmaceutical ingredients, agreement title french : Harnessing the benefits of continuous crystallization to precisely control particular size_x000D_
distribution of active pharmaceutical ingredients, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-05-10, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year. (2017-2018 to 2018-2019), additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier. (2017-2018 à 2018-2019), owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada